Impact of Triglyceride-Glucose Index on the Risk of Inflammatory Bowel Disease

Wangdong FAN, Wenqian YU

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (2) : 251-258.

PDF(769 KB)
Home Journals Acta Academiae Medicinae Sinicae
Acta Academiae Medicinae Sinicae

Abbreviation (ISO4): Acta Academiae Medicinae Sinicae      Editor in chief: Xuetao CAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(769 KB)
Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (2) : 251-258. DOI: 10.3881/j.issn.1000-503X.16205
Original Articles

Impact of Triglyceride-Glucose Index on the Risk of Inflammatory Bowel Disease

Author information +
History +

Abstract

Objective To investigate the impact of the triglyceride-glucose(TyG)index on the risk of inflammatory bowel disease(IBD).Methods Based on the data from UK Biobank,participants were allocated into three groups,TyG1(≤4.564),TyG2(4.564-4.808),and TyG3(≥4.808),according to tertiles of the TyG index.Kaplan-Meier curves were established to analyze the cumulative incidence of IBD.Further,Cox proportional hazard regression was employed to analyze the hazard ratio(HR)and its 95% confidential interval(95%CI)of each group.The same analysis was conducted for different subtypes(ulcerative colitis and Crohn’s disease)of IBD.Sensitive analysis based on the competing risk model was performed after excluding participants who were diagnosed within one year.Results A total of 116 423 participants were included in this study,with the median follow-up time of 12.56 years.The incidence densities of IBD in the TyG1,TyG2,and TyG3 groups were 4.47,5.94,and 6.50 per 10 000 person-year,respectively.The cumulative incidence of IBD increased with the rise in TyG,and Log-rank test results showed differences in cumulative incidence between groups(P<0.001).After adjusting the confounding factors,the HR(95%CI)of IBD in the TyG2 and TyG3 groups was 1.50(1.21-1.85)and 1.71(1.36-2.16),respectively.The results of the subgroup analysis after adjusting the confounding factors revealed that the HR(95%CI)of ulcerative colitis and Crohn’s disease in the TyG3 group was 1.48(1.16-1.74)and 2.27(1.51-3.42),respectively.The sensitive analysis yielded similar results after excluding participants who were diagnosed within one year.Conclusion A high TyG index indicates an increased risk of IBD and its subtypes.

Key words

triglyceride-glucose index / inflammatory bowel disease / ulcerative colitis / Crohn’s disease / risk factors

Cite this article

Download Citations
Wangdong FAN , Wenqian YU. Impact of Triglyceride-Glucose Index on the Risk of Inflammatory Bowel Disease[J]. Acta Academiae Medicinae Sinicae. 2025, 47(2): 251-258 https://doi.org/10.3881/j.issn.1000-503X.16205

References

[1]
Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease[J]. United European Gastroenterol J, 2022, 10(10):1047-1053.DOI:10.1002/ueg2.12319.
[2]
Aniwan S, Santiago P, Loftus EV Jr, et al. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries[J]. United European Gastroenterol J, 2022, 10(10):1063-1076.DOI:10.1002/ueg2.12350.
[3]
Agrawal M, Allin KH, Petralia F, et al. Multiomics to elucidate inflammatory bowel disease risk factors and pathways[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(6):399-409.DOI:10.1038/s41575-022-00593-y.
[4]
Tanner S, Katz J, Cominelli F, et al. Inflammatory bowel disease and helicobacter pylori:protective or present[J]. Inflamm Bowel Dis, 2023, 29(6):1005-1007.DOI:10.1093/ibd/izac202.
[5]
Zhong Y, Zhang Z, Lin Y, et al. The relationship between helicobacter pylori and Inflammatory bowel disease[J]. Arch Iran Med, 2021, 24(4):317-325.DOI:10.34172/aim.2021.44.
[6]
Carrillo-Palau M, Hernández-Camba A, Hernández Alvarez-Buylla N, et al. Insulin resistance is not increased in inflammatory bowel disease patients but is related to non-alcoholic fatty liver disease[J]. J Clin Med, 2021, 10(14):3062.DOI:10.3390/jcm10143062.
[7]
Doğan AN, Kahraman R, Akar T. Evaluation of insulin resistance and beta cell activity in patients with inflammatory bowel disease[J]. Eur Rev Med Pharmacol Sci, 2022, 26(11):3989-3994.DOI:10.26355/eurrev_202206_28969.
[8]
Nuñez P, García Mateo S, Quera R, et al. Inflammatory bowel disease and the risk of cardiovascular diseases[J]. Gastroenterol Hepatol, 2021, 44(3):236-242.DOI:10.1016/j.gastrohep.2020.09.002.
[9]
Saadh MJ, Pal RS, Arias-Gonzáles JL, et al. A mendelian randomization analysis investigates causal associations between inflammatory bowel diseases and variable risk factors[J]. Nutrients, 2023, 15(5):1202.DOI:10.3390/nu15051202.
[10]
Tao LC, Xu JN, Wang TT, et al. Triglyceride-glucose index as a marker in cardiovascular diseases:landscape and limitations[J]. Cardiovasc Diabetol, 2022, 21(1):68.DOI:10.1186/s12933-022-01511-x.
[11]
林艺鑫, 张力, 周静, 等. 累积TyG指数暴露对结直肠癌的发病风险:一项前瞻性队列研究[J]. 肿瘤代谢与营养电子杂志, 2023, 10(4):546-552.DOI:10.16689/j.cnki.cn11-9349/r.2023.04.014.
[12]
Wu Y, Xiong T, Tan X, et al. Frailty and risk of microvascular complications in patients with type 2 diabetes:a population-based cohort study[J]. BMC Med, 2022, 20(1):473.DOI:10.1186/s12916-022-02675-9.
[13]
Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire:12-country reliability and validity[J]. Med Sci Sports Exerc, 2003, 35(8):1381-1395.DOI:10.1249/01.MSS.0000078924.61453.FB.
[14]
Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease:east meets west[J]. J Gastroenterol Hepatol, 2020, 35(3):380-389.DOI:10.1111/jgh.14872.
[15]
Zhao M, Gönczi L, Lakatos PL, et al. The burden of inflammatory bowel disease in Europe in 2020[J]. J Crohns Colitis, 2021, 15(9):1573-1587.DOI:10.1093/ecco-jcc/jjab029.
[16]
Ghione S, Sarter H, Fumery M, et al. Dramatic increase in incidence of ulcerative colitis and crohn’s disease(1988-2011):a population-based study of French adolescents[J]. Am J Gastroenterol, 2018, 113(2):265-272.DOI:10.1038/ajg.2017.228.
[17]
Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980-2013:a nationwide cohort study[J]. Aliment Pharmacol Ther, 2017, 45(7):961-972.DOI:10.1111/apt.13971.
[18]
van den Heuvel TRA, Jeuring SFG, Zeegers MP, et al. A 20-year temporal change analysis in incidence,presenting phenotype and mortality,in the Dutch IBDSL Cohort-Can diagnostic factors explain the increase in IBD incidence.[J]. J Crohns Colitis, 2017, 11(10):1169-1679.DOI:10.1093/ecco-jcc/jjx055.
[19]
Ng SC, Si HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:a systematic review of population-based studies[J]. Lancet, 2017, 390(10114):2769-2778.DOI:10.1016/S0140-6736(17)32448-0.
[20]
Titz B, Gadaleta RM, Lo Sasso G, et al. Proteomics and lipidomics in inflammatory bowel disease research:from mechanistic insights to biomarker identification[J]. Int J Mol Sci, 2018, 19(9):2775.DOI:10.3390/ijms19092775.
[21]
Francis KL, Alonge KM, Pacheco MC, et al. Diabetes exacerbates inflammatory bowel disease in mice with diet-induced obesity[J]. World J Gastroenterol, 2023, 29(33):4991-5004.DOI:10.3748/wjg.v29.i33.4991.
[22]
Kang Y, Park H, Choe BH, et al. The role and function of mucins and its relationship to inflammatory bowel disease[J]. Front Med(Lausanne), 2022,9:848344.DOI:10.3389/fmed.2022.848344.
[23]
Lewis JD, Abreu MT. Diet as a trigger or therapy for inflammatory bowel diseases[J]. Gastroenterology, 2017, 152(2):398-414.e6.DOI:10.1053/j.gastro.2016.10.019.
[24]
Owczarek D, Rodacki T, Domagała-Rodacka R, et al. Diet and nutritional factors in inflammatory bowel diseases[J]. World J Gastroenterol, 2016, 22(3):895-905.DOI:10.3748/wjg.v22.i3.895.
[25]
Okamura T, Hashimoto Y, Hamaguchi M, et al. Triglyceride-glucose index(TyG index)is a predictor of incident colorectal cancer:a population-based longitudinal study[J]. BMC Endocr Disord, 2020, 20(1):113.DOI:10.1186/s12902-020-00581-w.
[26]
Wang Y, Wang J, Liu L, et al. Baseline level and change trajectory of the triglyceride-glucose index in relation to the development of NAFLD:a large population-based cohort study[J]. Front Endocrinol(Lausanne), 2023,14:1137098.DOI:10.3389/fendo.2023.1137098.
[27]
Kim YM, Kim Y, Kim JH, et al. Triglyceride-glucose index is associated with gastroesophageal reflux disease and erosive reflux disease:a health checkup cohort study[J]. Sci Rep, 2022, 12(1):20959.DOI:10.1038/s41598-022-25536-0.
[28]
Liu T, Zhang Q, Wang Y, et al. Association between the TyG index and TG/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer[J]. BMC Cancer, 2022, 22(1):1007.DOI:10.1186/s12885-022-10100-w.
[29]
Xu G, Xu Y, Zheng T, et al. Type 2 diabetes and inflammatory bowel disease:a bidirectional two-sample Mendelian randomization study[J]. Sci Rep, 2024, 14(1):5149.DOI:10.1038/s41598-024-55869-x.
[30]
Jess T, Jensen BW, Andersson M, et al. Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study[J]. Clin Gastroenterol Hepatol, 2020, 18(4):881-888.e1.DOI:10.1016/j.cgh.2019.07.052.
[31]
Melnyk J, Stefanov DG, Sultan K. Inflammatory bowel disease and corticosteroid-induced diabetes mellitus[J]. Clin Gastroenterol Hepatol, 2021, 19(3):620.DOI:10.1016/j.cgh.2020.05.020.
[32]
Fuschillo G, Celentano V, Rottoli M, et al. Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes.A systematic review with meta-analysis[J]. Dig Liver Dis, 2023, 55(5):580-586.DOI:10.1016/j.dld.2022.08.017.
[33]
Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease:systematic review[J]. Gastroenterology, 2022, 162(4):1147-1159.e4.DOI:10.1053/j.gastro.2021.12.282.
PDF(769 KB)

Accesses

Citation

Detail

Sections
Recommended

/